Which U.S. telehealth platforms currently prescribe tirzepatide (Zepbound/Mounjaro) for weight loss or diabetes?
Executive summary
A growing set of U.S. telehealth companies now prescribe tirzepatide—marketed as Zepbound (approved for chronic weight management) and Mounjaro (approved for type 2 diabetes)—either as brand-name products through manufacturer-linked services or as compounded/cash-pay options through private telehealth clinics [1] [2] [3]. Major legitimate pathways include direct manufacturer/partner programs like LillyDirect and mainstream telehealth clinics such as Sesame Care, while a larger ecosystem of commercial telehealth vendors and compounding pharmacy programs (CoreAge RX, Brello Health, MEDVi, SynergyRx, Shed and others) advertise access to branded or compounded tirzepatide with varying oversight, pricing, and regulatory implications [4] [5] [1] [6] [7] [8] [9] [10].
1. Brand-name access: manufacturer and mainstream telehealth routes
Patients seeking FDA‑approved Zepbound or Mounjaro online will find formal manufacturer-linked and mainstream telehealth options: Eli Lilly’s LillyDirect offers telehealth access and home delivery of authentic Zepbound when prescribed [4] [5], and national telehealth clinics such as Sesame Care state that their providers can prescribe tirzepatide during online visits—while noting the clinical discretion required and distinguishing that Zepbound is approved for weight loss and Mounjaro for diabetes [1] [11].
2. Consumer telehealth brands that advertise branded prescribing and integrated delivery
A number of consumer-facing telehealth platforms advertise pathways to brand prescriptions and coordinated pharmacy fulfillment: WeightWatchers’ WW Clinic promotes Zepbound prescriptions with delivery via LillyDirect [5], and some mainstream telehealth weight‑loss services describe e‑prescribing to local or mail‑order pharmacies after online evaluation [2] [11]. These channels emphasize licensed clinician review, titration plans, and follow-up, mirroring the clinical steps used in trials [2] [5].
3. Cash‑pay and compounding telehealth ecosystem
Parallel to branded routes is a broad market of cash‑pay telehealth clinics and compounding pharmacy programs that offer compounded tirzepatide or lower‑cost monthly subscriptions; outlets named in reporting include CoreAge RX, Brello Health, MEDVi, SynergyRx, Shed (ShedRx), Peak Wellness and others that advertise nationwide or multi-state services and lower prices via compounding partnerships [6] [7] [8] [9] [10] [12]. Industry summaries and rankings list a dozen-plus platforms positioning compounded tirzepatide as a cheaper alternative, but they also warn compounded preparations are not FDA‑approved finished products and vary by pharmacy and state rules [3] [6] [9].
4. What the reporting says about indications and off‑label use
Documented distinctions matter: Zepbound is FDA‑cleared specifically for chronic weight management, while Mounjaro is approved for improving blood sugar control in type 2 diabetes; prescribing one versus the other depends on diagnosis, and weight‑loss use of Mounjaro remains off‑label even as many clinics treat patients without diabetes [1] [2] [3] [10]. Consumer sites and telehealth vendors largely mirror that regulatory split but also advertise off‑label weight management prescribing when clinicians deem it appropriate, a practice permitted clinically but carrying insurance and regulatory implications [3] [10].
5. Safety, regulatory and quality caveats to weigh
Reporting repeatedly flags safety, monitoring, and regulatory caveats: legitimate telehealth providers require clinician evaluation, follow‑up, and coordinate with licensed pharmacies, while compounding options carry distinct risks because compounded tirzepatide is not an FDA‑approved finished product and state rules on teleprescribing and in‑person requirements vary [3] [9] [7]. Consumer guidance in reviews stresses verifying prescriber credentials, pharmacy accreditation, pricing transparency and that clinics will not sell without a prescription [13] [9] [10].
6. How to interpret the landscape and pick a pathway
The evidence in the reporting shows two clear telehealth classes that currently prescribe tirzepatide in the U.S.: manufacturer/retail-linked telehealth programs and mainstream telehealth clinics that e‑prescribe brand products (e.g., LillyDirect, Sesame, WW Clinic), and a larger, commercialized cash/compounding sector offering compounded tirzepatide through platforms like CoreAge RX, Brello, MEDVi, SynergyRx and others—each with different price points, oversight models and regulatory tradeoffs that patients should verify before proceeding [4] [5] [1] [6] [7] [8] [9]. Reporting does not provide an exhaustive registry of every telehealth vendor in operation, so this summary reflects named providers in the available sources and the broader categories they represent [6] [3].